Cumberland (CPIX) director Caroline Young receives 1,800-share stock grant

Rhea-AI Filing Summary

Cumberland Pharmaceuticals director Caroline Young received a grant of 1,800 shares of Common Stock of CUMBERLAND PHARMACEUTICALS INC. The shares were awarded at a price of $2.80 per share. Following this compensation-related acquisition, she directly holds 35,109 shares of the company’s common stock.

Insider Trade Summary

Net Buyer: 1,800 shares

Net Buy 1 txn

Insider Young Caroline

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	1,800	$2.80	$5K

Holdings After Transaction: Common Stock — 35,109 shares (Direct)

FAQ

What insider transaction did Caroline Young report at CPIX?

Director Caroline Young reported receiving 1,800 shares of Cumberland Pharmaceuticals common stock. The shares were granted as a compensation-related award at a reported price of $2.80 per share, increasing her direct holdings to 35,109 shares after the transaction.

Was the Caroline Young CPIX Form 4 a purchase or a grant?

The Form 4 for Cumberland Pharmaceuticals director Caroline Young shows an acquisition classified as a grant or award. It is not an open-market purchase, but rather a compensation-related issuance of 1,800 common shares at a reported price of $2.80 per share.

How many CPIX shares does Caroline Young hold after this Form 4?

After receiving the 1,800-share award, Caroline Young holds 35,109 shares of Cumberland Pharmaceuticals common stock. This total reflects her direct ownership position as reported in the Form 4 filing following the compensation-related grant transaction.

What price per share is listed in Caroline Young’s CPIX grant?

The Form 4 filing lists a transaction price of $2.80 per share for the 1,800-share grant to Caroline Young. This figure describes the per-share value associated with the award of Cumberland Pharmaceuticals common stock reported in the filing.

Does the CPIX Form 4 show any stock sales by Caroline Young?

The disclosed Form 4 for Cumberland Pharmaceuticals shows only an acquisition classified as a grant or award of 1,800 shares to Caroline Young. It does not report any sales or dispositions of the company’s common stock in this specific filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 03/20/2026 - 05:21 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Young Caroline

(Last) (First) (Middle)

1600 WEST END AVENUE

SUITE 1300

(Street)

NASHVILLE TENNESSEE 37203

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CUMBERLAND PHARMACEUTICALS INC [ CPIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/18/2026		A		1,800	A	$2.8	35,109	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	Caroline Young by /s/ John Hamm as attorney-in-fact	03/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)